Positive News SentimentPositive NewsNASDAQ:ZSQR Coeptis Therapeutics (ZSQR) Stock Price, News & Analysis $2.41 -0.06 (-2.43%) As of 11:49 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Coeptis Therapeutics Stock (NASDAQ:ZSQR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Coeptis Therapeutics alerts:Sign Up Key Stats Today's Range$2.35▼$2.5750-Day Range$2.29▼$5.6652-Week Range$2.11▼$21.41Volume82,600 shsAverage Volume301,094 shsMarket Capitalization$127.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Coeptis Therapeutics was a biotechnology company focused on developing cell-based immunotherapies for cancer and other serious diseases. Its research centered on engineered immune cells, including CAR T-cell approaches designed to help the immune system recognize and attack diseased cells. The company’s development programs included therapies targeting blood cancers, as well as cell-therapy technologies intended to support broader treatment applications. These programs were investigational; Coeptis’s work focused on research and development rather than a portfolio of established, marketed medicines. Coeptis was based in the United States and built its development efforts through licensed technologies and collaborations. The company has since been associated with the name Z Squared and the ticker ZSQR, so its historical therapeutics focus may not describe its current business activities.AI Generated. May Contain Errors. Read More Coeptis Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreZSQR MarketRank™: 0.595409836065 of 5 starsCoeptis Therapeutics scored higher than 12% of companies evaluated by MarketBeat, and ranked 527th out of 592 stocks in the technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingCoeptis Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCoeptis Therapeutics has received no research coverage in the past 90 days.Read more about Coeptis Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Coeptis Therapeutics is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coeptis Therapeutics is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCoeptis Therapeutics has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.65% of the float of Coeptis Therapeutics has been sold short.Short Interest Ratio / Days to CoverCoeptis Therapeutics has a short interest ratio ("days to cover") of 10.73, which indicates bearish sentiment.Change versus previous monthShort interest in Coeptis Therapeutics has recently decreased by 5.46%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCoeptis Therapeutics does not currently pay a dividend.Dividend GrowthCoeptis Therapeutics does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentCoeptis Therapeutics has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Technology companies.News Coverage This WeekMarketBeat has tracked 1 news article for Coeptis Therapeutics this week, compared to 1 article on an average week. Company Ownership3.0 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $3,920.00 in company stock, which represents 0.0028% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Coeptis Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,920.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders24.25% of the stock of Coeptis Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions13.88% of the stock of Coeptis Therapeutics is held by institutions.Read more about Coeptis Therapeutics' insider trading history. Receive ZSQR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coeptis Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZSQR Stock News HeadlinesZ Squared Advances Debt-Free Arkansas AI Campus as Build-Out Bottlenecks Constrain Major MarketsNovember 5, 2026 | prnewswire.comZ Squared Inc. Appoints Chief Technology Officer Jeffery Harris to Board of DirectorsNovember 4, 2026 | prnewswire.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 13 at 1:00 AM | Profits Run (Ad)Z Squared Begins Site Planning and Engineering at Energized Union County Campus in El Dorado, ArkansasOctober 30, 2026 | prnewswire.comZ Squared Inc. CEO David Halabu Discusses AI Data Center Strategy on Two Investor PodcastsSeptember 18, 2026 | prnewswire.comZ Squared Acquires Energized Arkansas Campus to Advance AI Infrastructure StrategySeptember 9, 2026 | prnewswire.comZ Squared CEO to Shareholders: "The Scarcest Thing in AI is Not Chips. It is Power.August 14, 2026 | prnewswire.comZ Squared Inc. Signs Definitive Agreement to Acquire 100% of Paradox Data and Its Union County CampusAugust 3, 2026 | prnewswire.comSee More Headlines ZSQR Stock Analysis - Frequently Asked Questions How have ZSQR shares performed this year? Coeptis Therapeutics' stock was trading at $14.25 on January 1st, 2026. Since then, ZSQR shares have decreased by 81.2% and is now trading at $2.68. How were Coeptis Therapeutics' earnings last quarter? Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) issued its earnings results on Thursday, August, 13th. The company reported ($0.28) EPS for the quarter. The firm earned $1.58 million during the quarter. Coeptis Therapeutics had a negative trailing twelve-month return on equity of 49.45% and a negative net margin of 773.72%. When did Coeptis Therapeutics' stock split? Shares of Coeptis Therapeutics reverse split on Tuesday, December 31st 2024.The 1-20 reverse split was announced on Friday, December 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Coeptis Therapeutics? Shares of ZSQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Coeptis Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Coeptis Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), FingerMotion (FNGR), Cosmos Health (COSM), Digital Brands Group (DBGI), Advanced Micro Devices (AMD) and Bollinger Innovations (BINI). Company Calendar Last Earnings8/13/2026Today11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 4 days ago, ZSQR's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorTechnology Industry Software Sub-IndustryApplication Software Current SymbolNASDAQ:ZSQR Previous SymbolNASDAQ:COEP CIK1759186 Webir.zsquaredinc.com Phone(954) 400-9994FaxN/AEmployees6Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.92 million Net Margins-773.72% Pretax Margin-953.59% Return on Equity-49.45% Return on Assets-46.88% Debt Debt-to-Equity RatioN/A Current Ratio7.66 Quick Ratio7.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.63 per share Price / Book0.90Miscellaneous Outstanding Shares53,000,000Free Float40,148,000Market Cap$126.14 million OptionableNot Optionable Beta-0.29 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:ZSQR) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredTrump, Schiff and Dalio all point to the same warning signIn 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't made whole unt...USA Capital Gold | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
